Advancements in Targeting the Androgen Receptor Pathway in Metastatic Prostate Cancer

An expert provides an overview of metastatic prostate cancer, including information on how it advances, patient prognosis, and what factors influence outcomes.

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice.

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.

This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.

Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.